Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Merck & Co., Inc. (“Merck”) (NYSE: MRK) securities between October 26, 2023 and February 3, 2025, inclusive (the “Class Period”).
Merck is a global healthcare company that operates through its Pharmaceutical and Animal Health segments. One of Merck’s primary products from its Pharmaceutical segment is the GARDASIL vaccine, which is for the prevention of HPV and certain HPV-related cancers.
The complaint alleges that, throughout the Class Period, Defendants provided these overwhelmingly positive statements to investors about expected revenue of $11 billion from sales of GARDASIL by 2030 while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GARDASIL 's demand in China; notably, that Merck lacked visibility into demand for GARDASIL in China among eligible and otherwise targeted populations, resulting in the inflated inventory of its distributor, Zhifei.
Current Status of Case:
On February 20, 2026, the Lead Plaintiffs filed an Amended Complaint. This action is ongoing.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.